top of page

SEGOVA
Boosting Spectrum

Ovarian Rejuvenation Program

Microscopic View of Embryonic Stem Cells_edited.jpg

SEGOVA Boosting Spectrum (SEGOVA BS) is a set of procedures created to enhance and extend the positive effects of SEGOVA program.

SEGOVA NEW GENERATION is a biological therapy whose effects depend on the potency, number, and type of cells and their products used in the therapy. Additionally, the effects also rely on the biological characteristics of the cells and tissues whose function we aim to regenerate.

Considering the significant individual differences in response to biological therapies, continuous reproductive and endocrine monitoring after the procedure and the choice of therapy are of great importance.

Nevertheless, 85% of patients experience hormonal improvement as a result of the success of SEGOVA. We observe reproductive enhancement with follicles in nearly two-thirds of cases, and pregnancy is attained in 15%. For patients who experienced improvement but were unable to achieve pregnancy, SEGOVA booster procedures are presented as an alternative. It's important to note that in cases where there was no improvement after SEGOVA, the booster technologies are not anticipated to yield positive effects.

Our primary intention is to capitalize on every opportunity to obtain eggs and embryos. To this end, supportive therapies have been developed that, based on individual characteristics, could increase the chance of achieving one's own offspring.

SEGOVA Boosting Procedures:

1. HcPRP
 

The latest generation of autologous activated highly concentrated growth factor hcPRP (daily procedure).

  • Processing of blood sample for growth factor extraction

  • Optimization of platelet and growth factor concentration

  • Preparation of autologous thrombin

  • Ultrasound-guided intra-ovarian application of hcPRP(+FSH/LH+GH+hCG)*

  • Ultrasound-guided sub endometrial application of hcPRP+hCG

 

2. HcPRP with BRF
 

The latest generation of autologous activated highly concentrated growth factor hcPRP with bio-regenerative fibrin scaffold BRF (daily procedure).

  • Processing of blood sample for growth factor extraction

  • Optimization of platelet and growth factor concentration

  • Isolation of bio-regenerative fibrin

  • Preparation of autologous thrombin

  • Ultrasound-guided intraovarian injections of BRF and hcPRP

    (+FSH/LH+GH+hCG)*

  • Ultrasound-guided sub endometrial application of BRF substrate and

    hcPRP+hCG

 

3. IN VITRO ACTIVATION OF OVARIAN TISSUE  (IVA) - LIGHT
 

Non-operative In Vitro Activation of ovarian biopsied tissue with the latest generation of autologous activated highly concentrated growth factors hcPRP with bio-regenerative fibrin BRF scaffold (Non-operative - daily procedure).

  • Processing of blood sample for growth factor extraction

  • Optimization of platelet and growth factor concentration

  • Isolation of bio-regenerative fibrin (substrate)

  • Preparation of autologous thrombin

  • Ultrasound-guided sub endometrial application of BRF substrate and hcPRP+hCG

  • Sampling of ovarian cortex tissue (Ultrasound-guided multiple ovarian biopsies)

  • Tissue processing for in vitro activation (micro fragmentation of ovarian cortex tissue under the film of activated autologous highly concentrated PRP with growth factors)

  • Ultrasound-guided re-transplantation of processed tissue substrate with activated autologous hcPRP (+FSH/LH

4. SEGO


The latest generation of autologous activated highly concentrated growth factors hcPRP and mSC bone marrow stem cells with bio-regenerative fibrin BRF scaffold (daily procedure).

  • Processing of blood sample for growth factor extraction

  • Optimization of platelet and growth factor concentration

  • Isolation of bio-regenerative fibrin (substrate)

  • Preparation of autologous thrombin

  • Iliac crest puncture

  • Sampling and processing of bone marrow (stem cell processing)

  • Ultrasound-guided sub endometrial application of BRF substrate and

    hcPRP+hCG

  • Ultrasound-guided intra-ovarian application of BRF substrate, retransplantation of processed stem cells, and hcPRP (+FSH/LH+GH+hCG)*

5. SEGOVA NG - NEW GENERATION - LIGHT


Non-operative In Vitro Activation of ovarian tissue with the latest generation of autologous activated highly concentrated hcPRP growth factors and mesenchymal stem cells mSC on bio-regenerative fibrin BRF substrate (daily procedure).

  • Processing of blood sample for growth factor extraction

  • Optimized platelet and growth factor concentration

  • Isolation of bio-regenerative fibrin (substrate)

  • Preparation of autologous thrombin

  • Iliac crest puncture

  • Sampling and processing of bone marrow (stem cell processing)

  • Ultrasound-guided multiple ovarian biopsies for tissue processing

  • Tissue processing for in vitro activation (micro fragmentation and incubation

    of sampled tissue under film of highly concentrated growth factors)

  • Iliac crest puncture

  • Sampling and processing of bone marrow (stem cell processing)

  • Ultrasound-guided sub endometrial application of BRF substrate and

    hcPRP+hCG

  • Intraovarian ultrasound-guided re-transplantation of BRF substrate,

processed activated tissue, mCS, and hcPRP (+FSH/LH+GH+hCG)*

*Optional

bottom of page